Exosomes are rapidly emerging as one of the most promising frontiers in regenerative medicine, offering the therapeutic ...
As BIO Asia–Taiwan 2026 brought the region’s biotechnology and healthcare ecosystem together in Taip...
Antibody-drug conjugates, GLP-1, dementia. Three Special Forums at BIO Asia-Taiwan 2026, three unrelated areas of medici...
On Wednesday the keynote argued that when AI compresses discovery, the constraint simply relocates: to manufacturing, ca...
Taiwan’s ambition to become one of Asia’s most consequential biotechnology hubs received a powerful ...
BIOSPECTRUM ASIA · DAY TWO ROUND-UP Day 1 belonged to the plenaries and the press. Day 2 was when ...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
The pharmaceutical industry’s innovation equation is changing. Developing an entirely new molecu...
The global CDMO market is moving beyond the era when manufacturing capacity alone defined competitive ...
As BioSpectrum Asia reports on the ground from BIO Asia–Taiwan 2026, being held from July 15–19 in T...
Longevity has never had a science problem so much as a business model problem. No regulator anywhere approves a drug for...
Every host city wants the same thing from an event like this: not the visit, but the verdict. What made the press meet w...
There is a particular energy to the first thirty minutes of a conference that knows exactly what it wants to say. As the...
